Innovating Works

ECONOMICS

Financiado
In cellular conformations of microRNA-34a via magnetic resonance
microRNA-34a (miR-34a) is mis-regulated in ~75% of cancers and is considered a promising drug target. In a recent clinical trial, miR-34a was used against terminal liver cancer showing promising result with remission of 3 patients... microRNA-34a (miR-34a) is mis-regulated in ~75% of cancers and is considered a promising drug target. In a recent clinical trial, miR-34a was used against terminal liver cancer showing promising result with remission of 3 patients. However, mortality remained high and was attributed to its ability to target multiple mRNAs. Project ECONOMICS will investigate this issue by elucidating the underlying structure and dynamics of multiple miR-34a:mRNA complexes using NMR spectroscopy and molecular dynamic simulations. This will provide information about the conformation of miR-34a which is mRNA specific. This can further be stabilized by mutations to increase target specificity of miR-34a leading to an improvement in clinical trial results. miR-34a targets and binds the 3’-untranslated-region (3’-UTR) of ~100 mRNAs via the RNA-induced silencing complex, resulting in downregulation of the associated genes. Recently, it was discovered that miR-34a attains a high energy excited state (ES) conformation for mRNA encoding gene SIRT1. Stabilizing this ES resulted in a two-fold increase in gene repression. Can miR-34a have a similar ES for other genes implicated in various cancers? This will be studied by exploring the structure and dynamics of miR-34a when complexed with 3’-UTR of the mRNA encoding the genes HNF4a, NOTCH1, NOTCH2, DLL1 and WNT1. Cellular environment is proposed to affect the ES of miR-34a, therefore a detailed conformational landscape of miR-34a:mRNA complexes will be mapped by comparing both in vitro and in live human cells (cancerous and non-cancerous). This study will provide targeting rules for microRNA within the cell and insight into its regulatory mechanism. This information will improve the efficiency RNA based drug development, giving a competitive edge to EU’s pharmaceutical industry, and ultimately realizing Europe’s Beating Cancer plan to achieve long-term survival of 70% patients with cancer by 2035. ver más
31/12/2024
UU
207K€
Duración del proyecto: 30 meses Fecha Inicio: 2022-06-09
Fecha Fin: 2024-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-09
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 207K€
Líder del proyecto
UPPSALA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5